BACKGROUND: A subset of children with asthma respond better to leukotriene receptor antagonists than to inhaled corticosteroids. Information is needed to identify children with these preferential responses. OBJECTIVE: We sought to determine whether the ratio of urinary leukotriene E(4) (LTE(4)) to fractional exhaled nitric oxide (FE(NO)) delineates children with preferential responsiveness to montelukast compared with fluticasone propionate (FP) therapy. METHODS: Data from 318 children with mild-to-moderate asthma enrolled in 2 National Heart, Lung, and Blood Institute Childhood Asthma Research and Education Network studies (Characterizing the Response to aLeukotriene Receptor Antagonist and an Inhaled Corticosteroid [CLIC] and the Pediatric Asthma Controller Trial [PACT]) were analyzed. The association between LTE(4)/FE(NO) ratios at baseline and improved lung function or asthma control days (ACDs) with montelukast and FP therapy was determined, and phenotypic characteristics related to high ratios were assessed. RESULTS: LTE(4)/FE(NO) ratios were associated with a greater response to montelukast than FP therapy for FEV(1) measurements (2.1% increase per doubling of ratio, P = .001) and for ACDs per week (0.3-ACD increase, P = .009) in the CLIC study. In PACT the ratio was associated with greater ACD responsiveness to MT than FP therapy (0.6 ACD increase, P=.03) [corrected]. In a combined study analysis, LTE(4): FE(NO) ratios were associated with greater response to MT than FP therapy for FEV(1) (1.8% increase, P =.0005) and ACDs (0.4 increase, P =.001)[corrected].Children with LTE(4)/FE(NO) ratios at or above the 75th percentile were likely (P < .05) to be younger and female and exhibit lower levels of atopic markers and methacholine reactivity. CONCLUSION: LTE(4)/FE(NO) ratios predict a better response to montelukast than FP therapy in children with mild-to-moderate asthma. Copyright (C) 2010 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.
RCT Entities:
BACKGROUND: A subset of children with asthma respond better to leukotriene receptor antagonists than to inhaled corticosteroids. Information is needed to identify children with these preferential responses. OBJECTIVE: We sought to determine whether the ratio of urinary leukotriene E(4) (LTE(4)) to fractional exhaled nitric oxide (FE(NO)) delineates children with preferential responsiveness to montelukast compared with fluticasone propionate (FP) therapy. METHODS: Data from 318 children with mild-to-moderate asthma enrolled in 2 National Heart, Lung, and Blood Institute Childhood Asthma Research and Education Network studies (Characterizing the Response to a Leukotriene Receptor Antagonist and an Inhaled Corticosteroid [CLIC] and the Pediatric Asthma Controller Trial [PACT]) were analyzed. The association between LTE(4)/FE(NO) ratios at baseline and improved lung function or asthma control days (ACDs) with montelukast and FP therapy was determined, and phenotypic characteristics related to high ratios were assessed. RESULTS: LTE(4)/FE(NO) ratios were associated with a greater response to montelukast than FP therapy for FEV(1) measurements (2.1% increase per doubling of ratio, P = .001) and for ACDs per week (0.3-ACD increase, P = .009) in the CLIC study. In PACT the ratio was associated with greater ACD responsiveness to MT than FP therapy (0.6 ACD increase, P=.03) [corrected]. In a combined study analysis, LTE(4): FE(NO) ratios were associated with greater response to MT than FP therapy for FEV(1) (1.8% increase, P =.0005) and ACDs (0.4 increase, P =.001)[corrected].Children with LTE(4)/FE(NO) ratios at or above the 75th percentile were likely (P < .05) to be younger and female and exhibit lower levels of atopic markers and methacholine reactivity. CONCLUSION: LTE(4)/FE(NO) ratios predict a better response to montelukast than FP therapy in children with mild-to-moderate asthma. Copyright (C) 2010 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.
Authors: Stephen C Lazarus; Vernon M Chinchilli; Nancy J Rollings; Homer A Boushey; Reuben Cherniack; Timothy J Craig; Aaron Deykin; Emily DiMango; James E Fish; Jean G Ford; Elliot Israel; James Kiley; Monica Kraft; Robert F Lemanske; Frank T Leone; Richard J Martin; Gene R Pesola; Stephen P Peters; Christine A Sorkness; Stanley J Szefler; Michael E Wechsler; John V Fahy Journal: Am J Respir Crit Care Med Date: 2007-01-04 Impact factor: 21.405
Authors: J F Maspero; E Dueñas-Meza; B Volovitz; C Pinacho Daza; L Kosa; F Vrijens; J A Leff Journal: Curr Med Res Opin Date: 2001 Impact factor: 2.580
Authors: Neil W Johnston; Piush J Mandhane; Jennifer Dai; Joanne M Duncan; Justina M Greene; Kim Lambert; Malcolm R Sears Journal: Pediatrics Date: 2007-09 Impact factor: 7.124
Authors: Ronina A Covar; Stanley J Szefler; Richard J Martin; D A Sundstrom; Philip E Silkoff; James Murphy; David A Young; Joseph D Spahn Journal: J Pediatr Date: 2003-05 Impact factor: 4.406
Authors: Robert C Strunk; Stanley J Szefler; Brenda R Phillips; Robert S Zeiger; Vernon M Chinchilli; Gary Larsen; Kevin Hodgdon; Wayne Morgan; Christine A Sorkness; Robert F Lemanske Journal: J Allergy Clin Immunol Date: 2003-11 Impact factor: 10.793
Authors: Jun Nagai; Barbara Balestrieri; Laura B Fanning; Timothy Kyin; Haley Cirka; Junrui Lin; Marco Idzko; Andreas Zech; Edy Y Kim; Patrick J Brennan; Joshua A Boyce Journal: J Clin Invest Date: 2019-12-02 Impact factor: 14.808
Authors: Anne M Fitzpatrick; Daniel J Jackson; David T Mauger; Susan J Boehmer; Wanda Phipatanakul; William J Sheehan; James N Moy; Ian M Paul; Leonard B Bacharier; Michael D Cabana; Ronina Covar; Fernando Holguin; Robert F Lemanske; Fernando D Martinez; Jacqueline A Pongracic; Avraham Beigelman; Sachin N Baxi; Mindy Benson; Kathryn Blake; James F Chmiel; Cori L Daines; Michael O Daines; Jonathan M Gaffin; Deborah Ann Gentile; W Adam Gower; Elliot Israel; Harsha Vardhan Kumar; Jason E Lang; Stephen C Lazarus; John J Lima; Ngoc Ly; Jyothi Marbin; Wayne Morgan; Ross E Myers; J Tod Olin; Stephen P Peters; Hengameh H Raissy; Rachel G Robison; Kristie Ross; Christine A Sorkness; Shannon M Thyne; Stanley J Szefler Journal: J Allergy Clin Immunol Date: 2016-10-21 Impact factor: 10.793